GLPwatch
Papers (10373)
Page 50 of 173, ranked by citation count.
- Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes.
- Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
- Lixisenatide: first global approval.
- Anti-inflammatory and pro-healing impacts of exendin-4 treatment in Zucker diabetic rats: Effects on skin wound fibroblasts.
- Exenatide ameliorates hydrogen peroxide-induced pancreatic β-cell apoptosis through regulation of METTL3-mediated m<sup>6</sup>A methylation.
- Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.
- Circulating microRNA-375 as biomarker of pancreatic beta cell death and protection of beta cell mass by cytoprotective compounds.
- Thyroid safety in patients treated with liraglutide.
- Liraglutide: from clinical trials to clinical practice.
- Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells.
- Protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase pathway in diabetes mellitus.
- Exendin-4-encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes.
- Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-Induced Obesity.
- The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
- Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life.
- Transient neonatal diabetes mellitus gene Zac1 impairs insulin secretion in mice through Rasgrf1.
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.
- Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
- Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.
- Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.
- The effect of liraglutide on the proliferation, migration, and osteogenic differentiation of human periodontal ligament cells.
- Semaglutide and pregnancy.
- Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression.
- Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management.
- A spectroscopic and molecular dynamics study on the aggregation process of a long-acting lipidated therapeutic peptide: the case of semaglutide.
- Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells.
- GLP-1R Agonist Liraglutide Attenuates Inflammatory Reaction and Neuronal Apoptosis and Reduces Early Brain Injury After Subarachnoid Hemorrhage in Rats.
- Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
- Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats.
- Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients.
- MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.
- Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus.
- Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance.
- Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres.
- Exendin-4 relieves the inhibitory effects of high glucose on the proliferation and osteoblastic differentiation of periodontal ligament stem cells.
- A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus.
- Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.
- GLP-1 based agents and acute pancreatitis : drug safety falls victim to the three monkey paradigm.
- Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.
- Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs.
- Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus.
- Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.
- Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.
- Exendin-4 stimulates islet cell replication via the IGF1 receptor activation of mTORC1/S6K1.
- Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
- GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.
- Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.
- Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.
- Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes.
- Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases.
- Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus.
- Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.
- EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
- Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
- Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.
- Characterization of human pancreatic progenitor cells.
- The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases.
- Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice.
- Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
- Determining predictors of response to exenatide in type 2 diabetes.